natgillin/translations-raw huggingface dataset:
DaTSCAN should only be used in adult patients referred by physicians experienced in the management of movement disorders and/or dementia.
DaTSCAN se smije koristiti samo u odraslih pacijenata prema preporuci liječnika s iskustvom u liječenju poremećaja pokreta i/ili demencije.
DAUN (45 mg/m2/day bolus, IV): days 1 and 2
DAUN (45 mg/m²/dan bolus, i.v.): dani 1 i 2
Daunorubicin 30 mg/m2 i.v., days 1-3, 15-16;
Daunorubicin 30 mg/m² i.v., dani 1-3, 15-16;
Daunorubicin 30 mg/m2 i.v., days 1-3, 15-16; V
Daunorubicin 30 mg/m² i.v., dani 1-3, 15-16;
Daunorubicin 30 mg/m2 i.v., days 1-3, 15-16; VCR 2 mg total dose i.v., days 1, 8, 15, 22; CP 750 mg/m2 i.v., days 1, 8; prednisone
Daunorubicin 30 mg/m2 i.v., dani 1-3, 15-16; VCR 2 mg ukupna doza i.v., dani 1, 8, 15, 22; CP 750 mg/m2 i.v., dani 1, 8; prednizon
Daunorubicin 60 mg/ m2 i.v. (1 h), days 1-3;
Daunorubicin 60 mg/m2 i.v. (1 h), dani 1-3;
Daunorubicin 60 mg/m2 i.v. (1 h), days 1-3;
Daunorubicin 60 mg/m2 i.v. (1 h), dani 1-3;
Daunorubicin, doxorubicin, imatinib, irinotecan, lapatinib, mitoxantrone or topotecan: careful monitoring for any occurrence of drug toxicity, and dose reduction if required.
Daunorubicin, doksorubicin, imatinib, irinotekan, lapatinib, mitoksantron ili topotekan: paţljivo praćenje radi mogućeg razvoja toksičnosti lijeka i po potrebi smanjenje doze.
daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer
danorubicin, doksorubicin, paklitaksel ili topotekan za rak
daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer
daunorubicin, doksorubicin, paklitaksel ili topotekan za liječenje raka
Daxas 500 micrograms
Daxas 500 mikrograma
Daxas 500 micrograms film-coated tablets roflumilast
Daxas 500 mikrograma filmom obložene tablete roflumilast
Daxas has been compared with placebo (a dummy treatment) in two main studies involving over 3,000 adults with severe COPD who had had at least one flare-up of their disease in the past year.
Daxas je uspoređen s placebom (lažno liječenje) u dva glavna ispitivanja koja su obuhvatila više od 3000 odraslih osoba s teškim KOPB-om kojima se bolest pogoršala barem jedanput tijekom prošle godine.
Daxas has been studied in clinical trials for up to one year.
U kliničkim ispitivanjima ispitana je primjena Daxasa u trajanju do godine dana.
Daxas is a medicine that contains the active substance roflumilast.
Daxas je lijek koji sadrži djelatnu tvar roflumilast.
Daxas is not indicated as rescue medicinal product for the relief of acute bronchospasms.
Daxas nije indiciran kao lijek za hitno ublažavanje akutnog bronhospazma.
Daxas is not recommended if you have one or more of the following diseases: severe immunological diseases such as HIV infection, multiple sclerosis (MS), lupus erythematosus (LE) or progressive multifocal leukoencephalopathy (PML)
Daxas se ne preporučuje ako imate jednu ili više sljedećih bolesti: tešku imunološku bolest poput HIV-infekcije, multiple skleroze (MS), eritemskog lupusa (LE) ili progresivne multifokalne leukoencefalopatije (PML)
Daxas is not recommended in patients with a history of depression associated with suicidal ideation or behaviour.
Daxas se ne preporučuje bolesnicima koji u povijesti bolesti imaju depresiju povezanu sa suicidalnim mislima ili ponašanjem.
Daxas is not used on its own but as an ‘add-on’ to treatment with bronchodilators (medicines that widen the airways in the lungs).
Daxas se ne koristi kao samostalni lijek nego kao dodatak liječenju bronhodilatatorima (lijekovima koji šire dišne puteve u plućima).
Daxas is to be used in addition to bronchodilators.
Libertek treba koristiti kao dodatak bronhodilatatorima.
Daxas is used to treat severe chronic obstructive pulmonary disease (COPD) in adults who have chronic bronchitis (long-term inflammation of the airways), and whose COPD flares up frequently.
Daxas se koristi za liječenje teške kronične opstruktivne plućne bolesti (KOPB) kod odraslih osoba koje imaju kronični bronhitis (dugotrajnu upalu dišnih puteva) i kod kojih KOPB često pogoršava.
Daxas may need to be taken for several weeks to achieve its effect (see section 5.1).
Daxas je ponekad potrebno uzimati više tjedana da bi se postigao učinak (vidjeti dio 5.1).
Daxas should not be used by children and adolescents under 18 years of age.
Daxas nije namijenjen djeci i adolescentima mlađim od 18 godina.
Daxas was shown to be more effective than placebo at treating COPD.
Daxas se pokazao djelotvornijim od placeba u liječenju KOPB-a.
Day -- -- -- 1
Dan -- -- -- 1
Day -- -- Day 1 4
Dan -- -- Dan 1 4
Day 01
SCR – PRNT
Day 1
dan
Day 1
Dan 1
Day 1 - 21
od 1. do 21. dana
Day 1 - 21: 30 mg Day 22 and onwards: 20 mg
Dan 1-21: 30 mg Dan 22 i nadalje: 20 mg
Day 1 - 21: 30 mg Day 22 and onwards: 20 mg
od 1. do 21. dana: 30 mg od 22. dana nadalje: 20 mg
Day 1 - full dose (1,000 mg)
1. dan – puna doza (1000 mg)
Day 1 - full dose (1,000 mg).
1. dan – puna doza (1000 mg)
Day 1 amount of product
Dan 1 Količina proizvoda
Day 1 in combination with ondansetron 32 mg IV on Day 1 and dexamethasone 12 mg on Day 1, 8 mg on Day 2, and 8 mg twice daily on Days 3 and 4.
1. dana liječenja, u kombinaciji s ondanzetronom 32 mg primijenjenim intravenski 1. dana liječenja i deksametazonom u dozi od 12 mg 1. dana, 8 mg 2. dana te 8 mg dvaput na dan 3. i 4. dana liječenja.
Day 1 to 21: 15 mg 1 tablet twice a day (one 15 mg tablet in the morning and one in the evening) together with food.
Od 1. do 21. dana: 1 tableta od 15 mg dvaput na dan (jedna tableta od 15 mg ujutro i jedna tableta navečer) s hranom.
Day 1 to 21: One 15 mg tablet twice a day (one 15 mg tablet in the morning and one in the evening) together with food.
Od 1. do 21. dana: jedna tableta od 15 mg dvaput na dan (jedna tableta od 15 mg ujutro i jedna navečer) s hranom.
Day 1 to Day 30
Od 1. dana do 30. dana
Day 1 – 21
od 1. do 21. dana
Day 1 – full dose (1,000 mg).
1. dan – puna doza (1000 mg)
Day 1 – part of your first dose (100 mg)
1. dan – dio prve doze (100 mg)
Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
Dan 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
Day 1, prior to FOLFOX-4, every 2 weeks
prvog dana, prije FOLFOX-4 protokola, svaka 2 tjedna
Day 1-7 of white active tablet intake (see picture and schedule)
1.-7. dan uzimanja bijelih tableta s djelatnim tvarima (pogledajte sliku i raspored)
Day 10
dan dan
Day 10 1000/100 mg (n=21)
10. dan 1000/100 mg (n=21)
Day 14 (94 micrograms) Date
14. dan (94 mikrograma) Datum
Day 14 1000/100 mg (n=21)
14. dan 1000/100 mg (n=21)
Day 141
14. dan1
Day 15
Dan 15
Day 15 - end of treatment
15. dan - kraj liječenja
Day 15 - full dose (1,000 mg).
15. dan – puna doza (1000 mg)
Day 15 onward
Rukavice: za šake, zapešća i prste.
Day 15 onward: three capsules, three times a day (2403 mg/day)
Od 15. dana nadalje: tri kapsule, triput na dan (2403 mg/dan)
Day 15 – full dose (1,000 mg)
15. dan – puna doza (1000 mg)
Day 15: If Day 8 doses were given without modification:
15. dan: Ako doze 8. dana nisu bile promijenjene:
Day 15: IF Day 8 doses were withheld:
15. dan: Ako su doze 8. dana bile obustavljene:
Day 16
Dan 16
Day 18-24
18. – 24. dan
Day 18-24 of white active tablet intake (see picture and schedule)
18.- 24. dan uzimanja bijelih tableta s djelatnim tvarima (pogledajte sliku i raspored)
Day 180
Dan 180
Day 1: intravenous infusion of 250 mg/m2 rituximab.
1. dan: intravenska infuzija rituksimaba u dozi od 250 mg/m2.
Day 1: ≥1.5 x 109/L
1. dan: ≥ 1,5 x 109/l
Day 1: ≥100 x 109/L
1. dan: ≥ 100 x 109/l
Day 2
dan
Day 2
Dan 2
Day 2 amount of product
Dan 2 Količina proizvoda
Day 2 or Day 1 (continued) – remainder of first dose 900 mg
2. dan ili 1. dan (nastavak) – ostatak prve doze (900 mg)
Day 21 N=145
21. dan N=145
Day 22
Dan 22
Day 22 and onwards
od 22. dana nadalje
Day 22, 23, 24, 25, 26, 27, 28
22., 23., 24., 25., 26., 27., 28. dan
Day 23
Dan 23
Day 28 (n=198)
28. dan (n = 198)
Day 28 and then every two weeks after that (125 micrograms)
28. dan a zatim svaka dva tjedna nakon toga (125 mikrograma)
Day 28 and then every two weeks after that (125 micrograms)
28. dan, a zatim svaka dva tjedna nakon toga (125 mikrograma)
Day 281
7./14. dan1
Day 29
Dan 29
Day 29 p-value
p-vrijednost na Dan 29
Day 29 p-value
p-vrijednost na Dan 29.
Day 3
dan
Day 3 500/100 mg (n=22)
3. dan 500/100 mg (n=22)
Day 3 amount of product
Dan 3 Količina proizvoda
Day 31, mean (SD)
31. dan, srednja vrijednost (SD)
Day 35
35. dan
Day 365
365. dan
Day 4
dan
Day 4 - 7
4. - 7. dan
Day 4 500/100 mg (n=21)
4. dan 500/100 mg (n=21)
Day 42 a Day 180 Day 42 a Day 180
42. dan a 180. dan 42. dan a 180. dan
Day 42 N=1,488
42. dan N=1488
Day 42 N=145
42. dan N=145
Day 421
28. dan1
Day 43 to Day 1
43. dan do 1. dan
Day 5
dan
Day 56
56. dan
Day 6
dan
Day 6 & thereafter
6. dan i nadalje
Day 6 onwards
Od 6. dana nadalje
Day 7
dan dan
Day 7 500/100 mg (n=21)
7. dan 500/100 mg (n=21)
Day 7/141
0. dan1
Day 71
7. dan1
Day 8
Dan 8
Day 8
DANA
Day 8 - full dose (1,000 mg)
8. dan – puna doza (1000 mg)
Day 8 – 14
8. – 14. dan
Day 8 – End of treatment:
8. dan – kraj liječenja:
Day 8 – full dose (1,000 mg)
8. dan – puna doza (1000 mg)
Day 8-17 of white active tablet intake (see picture and schedule)
8.-17. dan uzimanja bijelih tableta s djelatnim tvarima (pogledajte sliku i raspored)
Day 9
dan
Day 9
Dan 9
Day Day
Dan Dan
Day Day Day Day 1 2 3 4
Dan Dan Dan Dan 1 2 3 4
Day of Cycle
Dan ciklusa
day treatment pack containing: 1 x 125 mg hard capsule and x 80 mg hard capsule
Pakiranje za trodnevno liječenje sadrži: 1 x 125 mg tvrdu kapsulu i x 80 mg tvrdu kapsulu
day treatment pack containing: 2 x 80 mg hard capsule
Pakiranje za dvodnevno liječenje sadrži: 2 x 80 mg tvrdu kapsulu
Day-to-day variability in glucose-lowering effect during one dosing interval (AUCGIR,τ,SS)
Varijabilnost učinka snižavanja razine glukoze dan za danom tijekom jednog intervala doziranja (AUCGIR,τ,SS)
Day-to-day variability in glucose-lowering effect from 2- 24 hours (AUCGIR2-24h,SS)
Varijabilnost učinka snižavanja razine glukoze dan za danom od 2-24 sata (AUCGIR2-24h,SS)
Day-to-day variability in glucose-lowering effect from 2-24 hours (AUCGIR2-24h,SS)
Varijabilnost učinka snižavanja razine glukoze dan za danom od 2-24 sata (AUCGIR2-24h,SS)
Day2
2. dan
days (for example Monday-
određene dane (na primjer,
Days (mean ± SD) from consent
Dani (srednja vrijednost ± SD) od
Days (mean ± SD) from consent
Dani (srednja vrijednost ± SD) od informiranog pristanka
Days (mean ± SD) from consent
Dani (srednja vrijednost ± SD) od pristanka
Days (mean ± SD) from injury
Dani (srednja vrijednost ± SD) od ozljede
Days 1 to 7: one capsule, three times a day (801 mg/day)
Od 1. do 7. dana: jedna kapsula, triput na dan (801 mg/dan)
Days 1 – 3:
1. – 3. dan:
Days 1-21
1. – 21. dan
DAYS 1-7
1. do 7.
Days 10–14
Dani 10-14
Days 17–21
Dani 17-21
Days 2 and 3: one 80 mg capsule each day
i 3. dan: jedna kapsula od 80 mg svakog dana
Days 2 and 3: one 80 mg capsule each day
i 3. dan: jedna kapsula od 80 mg svakog dana.
Days 23-28
Dani 23-28
Days 24-28
Dani 24-28
Days 3–7
Dani 3–7
Days 4 – 7:
4. – 7. dan:
Days 8 and 15: ≥1.0 x 109/L
8. i 15. dan: ≥ 1,0 x 109/l
Days 8 and 15: ≥75 x 109/L
8. i 15. dan: ≥ 75 x 109/l
Days 8 to 14: two capsules, three times a day (1602 mg/day)
Od 8. do 14. dana: dvije kapsule, triput na dan (1602 mg/dan)
Days after injection (2,770 MBq)
Dani nakon injekcije (2.770 MBq)
days if the toxicity does not recur.
nakon 7 dana ako se toksičnost ponovno ne javi.
Days of FSH stimulation required
Broj dana potrebnih za stimulaciju s FSH
Days of FSH stimulation required
Dani potrebne stimulacije FSH-om
Days to closure of last wound (mean ± SD)
Dani do zatvaranja posljednje rane (srednja vrijednost ± SD)
DB-week 48
tjedan 48
DCarbH (vs.
DCarbH (naspram ACD)
DD month YYYY
DD/MM/GGGG
DD/ MM/YYYY
DD MM GGGG
DD/MM/YYYY
25.04.2013.
DD/MM/YYYY
M.YYYY
DDI not studied
Interakcija između lijekova nije ispitana.
ddI+d4T (fasted)
nakon ddI+d4T (natašte)
De novo resistance in patients failing therapy in SINGLE, SPRING-2 and FLAMINGO
De novo rezistencija u bolesnika s neuspješnim odgovorom na liječenje u ispitivanjima SINGLE, SPRING-2 i FLAMINGO
De novo resistance to emtricitabine/lamivudine was seen in 4 cases, and also to rilpivirine in 2 cases, with a consequent cross resistance to efavirenz (2/2), nevirapine (2/2) and etravirine (1/2).
De novo rezistencija na emtricitabin/lamivudin opažena je u 4 slučaja, a na rilpivirin u 2 slučaja, s posljedičnom križnom rezistencijom na efavirenz (2/2), nevirapin (2/2) i etravirin (1/2).
de pointes, administration of
torsades de pointes, ne preporučuje
DE-51368 Leverkusen Germany
Bayer Animal Health GmbH DE-51368 Leverkusen Germany
De-worming at least 10 days prior to vaccination is recommended.
Dehelmintizacija se preporuča najmanje 10 dana prije cijepljenja.
DE: disease exacerbation
EB: egzacerbacija bolesti
DEAE-Dextran Ginseng
DEAE-dekstran ginseng
DEAE-Dextran Ginseng.
DEAE-dekstran Ginseng.
deafness
gluhoća
deafness
hipoakuzija
deafness neurosensory
neurosenzorička gluhoća
Deafness*, ear discomfort, hearing impaired
gluhoća*, nelagoda u uhu, oštećenje sluha
deafness, tinnitus
gluhoća, tinitus
Deafness, vertigo, earache
Gluhoća, vrtoglavica, bol u uhu
Deafness.
gluhoća
Dear Healthcare Professional letter
Pismo zdravstvenim djelatnicima
Dear Patient,
Poštovani bolesniče,
Death
mrt
Death (%)
Smrt (%)
Death (all-cause)
Smrt (bilo koji uzrok)
Death (inc sudden), Multi-organ failure, Injection site haemorrhage*, Hernia(inc hiatus)*, Impaired healing*, Inflammation, Injection site phlebitis*, Tenderness, Ulcer, Irritability, Non-cardiac chest pain, Catheter site
Smrt (uključujući iznenadnu), multiorgansko zatajenje, krvarenje na mjestu injiciranja*, hernija (uključujući hijatus)*, poremećaj cijeljenja*, upala, flebitis na mjestu injiciranja*, osjetljivost, ulkus, iritabilnost, bol u prsištu ne-srčanog porijekla, bol na mjestu katetera, osjećaj stranog tijela
Death (OS event):
Smrt (događaj ukupnog preživljenja):
Death c n (%)
Smrt c n (%)
Death due to bleeding*
Smrt zbog krvarenja
Death due to PAH as a component of the endpoint was observed in 16 (2.8%) patients on selexipag and 14 (2.4%) on placebo.
Smrt zbog PAH-a kao komponenta ciljne točke zabilježena je u 16 (2,8%) bolesnika koji su primali seleksipag i 14 (2,4%) bolesnika koji su primali placebo.
Death due to sepsis occurred in 1 % of patients.
Smrt uslijed sepse nastupila je u 1% bolesnika.
Death or permanent disability may occur following bleeding in the brain or other serious bleeding events bleeding in the eyes (eye haemorrhage)
Može doći do smrti ili trajnog invaliditeta nakon krvarenja u mozgu, kao i nakon drugih teških epizoda krvarenja krvarenje u očima (hemoragija oka)
Death or progression, n (%)
Smrt ili progresija, n (%)
Death without objective progression
Smrt bez objektivne progresije
death, or hospitalisation for worsening PAH,
mrt ili hospitalizacija zbog pogoršanja PAH-a
Death/MI/IDR/ST a
Smrt/MI/IDR/STa
Deaths (%)
Smrti (%)
Deaths (%)
Smrtni ishodi (%)
Deaths 6
ispitivanje
Deaths: AZA = 82, CCR = 113
Smrtnost: AZA = 82, CCR = 113
Debossed with "7285" on the other side of the tablet.
Oznaka "7285" utisnuta je na drugoj strani tablete.
Debossed with "7286" on the other side of the tablet.
Oznaka "7286" utisnuta je na drugoj strani tablete.
Debossed with "7287" on the other side of the tablet.
Oznaka "7287" utisnuta je na drugoj strani tablete.
Debossed with "7493" on the other side of the tablet.
Oznaka "7493" utisnuta je na drugoj strani tablete.
Debrecen H-4042
Pallagi út 13 Debrecen H-4042 Mađarska
Debrecen H-4042 Hungary
Debrecen H-4042 Mađarska
Debris from selamectin- treated pets kills flea eggs and larvae not previously exposed to selamectin and thus may aid in the control of existing environmental flea infestations in areas to which the animal has access.
Debris s ljubimaca tretiranih selamektinom ubija jaja buha i larve koje prethodno nisu bile izložene selamektinu i tako može pomoći u kontroliranju postojećih infestacija buhama u okolišu u područjima u koja životinja ima pristup.
December 18, 2012
18. prosinca 2012.
December 19, 2011
19. prosinca 2011.
December 20,
20. prosinca 2012.
December 2015
prosinac 2015.
December 2018
prosinac 2018.
December 2023
2023.
December 30,
30. prosinca 2010.
December 30, 2010 data cut-off date (y)
Podaci do zaključno 30. prosinca 2010. (y)
Decide on an injection area – upper arm, thigh, buttock, or abdomen (see below).
Odlučite se za područje ubrizgavanja – nadlaktica, bedro, stražnjica ili trbuh (pogledajte ispod).
Decide where to inject Nivestim - find a place on the front of your abdomen or the front of your thigh.
Odaberite gdje ćete ubrizgati Nivestim – pronađite mjesto na prednjoj strani trbuha ili prednjoj strani bedara.
Decide where you are going to inject the medicine.
Odlučite gdje ćete si injicirati lijek.
Decide where you are going to inject the medicine.
Odlučite gdje ćete ubrizgati lijek.
Decide where you will inject Ceplene.
Odlučite gdje ćete ubrizgati Ceplene.
Decision of dose increase has to be balanced with a higher risk of transaminases elevation.
Odluka o povećanju doze treba biti usklađena sa većim rizikom od povećanja transaminaza.
Decision to have patient move to home infusion should be made after evaluation and recommendation by the treating physician.
Odluka da se bolesnik prebaci na primjenu infuzije kod kuće smije se donijeti tek nakon procjene i preporuke liječnika specijalista koji liječi bolest.
Decision whether to discontinue YERVOY should be based on severity. c Patients with severe (Grade 3 or 4) endocrinopathy controlled with hormone replacement therapy may remain on therapy.
Odluka o prekidu primjene lijeka YERVOY treba se temeljiti na težini nuspojave. c Bolesnici s teškom (3. ili 4. stupnja) endokrinopatijom koja se kontrolira hormonskom nadomjesnom terapijom mogu ostati na terapiji.
Decitabine has been shown to be a weak inhibitor of P-gp mediated transport in vitro and is therefore also not expected to affect P-gp mediated transport of co-administered medicinal products (see section 5.2).
Decitabin se pokazao kao slabi inhibitor transporta posredovanog P-glikoproteinom (P-gp) in vitro, stoga se ne očekuje da će utjecati na P-gp posredovani transport istovremeno primjenjivanih lijekova (vidjeti dio 5.2).
Decitabine Vdss in cancer patients is large indicating distribution of the drug into peripheral tissues.
Volumen distribucije decitabina u stanju dinamičke ravnoteže (Vdss) velik je u bolesnika s rakom, što ukazuje na distribuciju lijeka u periferna tkiva.
Decline of less than 10%
Pad manji od 10
Decompensated cardiac failure if not under close medical supervision.
Dekompenzirano zatajenje srca ako nije pod pomnim nadzorom liječnika.
Decompensated cardiac failure if not under close medical supervision.
Dekompenzirano zatajenje srca, ako nije pod strogim medicinskim nadzorom.
decompensated liver disease (see sections 4.4, 4.8 and 5.1).
dekompenziranom bolešću jetre (vidjeti dijelove 4.4, 4.8 i 5.1).
decompensated liver disease in combination with a second agent without cross-resistance to Hepsera.
dekompenziranom bolešću jetre u kombinaciji s drugim lijekom bez križne reistencije na Hepseru.
decompensated liver disease in combination with a second agent without cross-resistance to lamivudine (see section 4.2).
dekompenziranom bolešću jetre u kombinaciji s drugim lijekom bez križne rezistencije na lamivudin (vidjeti dio 4.2).
decompensated liver disease in combination with a second agent, without cross-resistance to lamivudine (see section 4.2).
dekompenziranom bolešću jetre u kombinaciji s drugim lijekom bez križne rezistencije na lamivudin (vidjeti dio 4.2).
decompensated severe hypertension,
dekompenzirana teška hipertenzija
decompensated severe hypertension,
dekompenzirana teška hipertenzija,
Decompensated states of heart failure.
Dekompenzacija srca.
decongestants
dekongestive
decongestants by oral or nasal route (such as phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline)
dekongestive koji se uzimaju kroz usta ili nos (kao što su fenilpropanolamin, fenilefrin, efedrin, oksimetazolin, nafazolin)
Decontaminate any spill with 10% caustic solution, or sodium hypochlorite (household chlorine bleach – 2 ml (0.5%): 1 litre water) solution.
U slučaju prolijevanja, dekontaminirajte površinu s 10% kaustične otopine ili otopinom natrijevog hipoklorita (bjelilo za domaćinstvo – 2 ml (0,5%): 1 litra vode).
Decontaminate any spill with 10% caustic solution, or sodium hypochlorite (household chlorine bleach – 2 ml (0.5%): 1 litre water) solution.
U slučaju prolijevanja, dekontaminirajte površinu s 10% kaustične otopine ili otopinom natrijevog hipoklorita (klorno bjelilo za domaćinstvo – 2 ml (0,5%): 1 litra vode).
decrease
manjenje
Decrease
sniziti
Decrease at weekly intervals in increments of:
Smanjivanje doze u razmacima od tjedan dana za:
decrease cobicistat plasma
primjena nevirapina i kobicistata
Decrease dose to: 2.0 mg/kg body weight
Smanjite dozu na: 2,0 mg/kg tjelesne težine
Decrease in 6MWD due to PH
smanjenje 6MWD zbog PH
decrease in albumin in the blood
niženje razine albumina u krvi
Decrease in ANC levels below 500 cells/mm3 was observed in 13% and 11% of patients receiving Pegasys monotherapy and combination therapy, respectively.
Smanjenje razina ABN na manje od 500 stanica/mm3 primijećeno je u 13% bolesnika koji su primali samo Pegasys, odnosno u 11% bolesnika koji su primali kombinirano liječenje.
Decrease in appetite or anorexia with a mean duration of 45 days and 18 days, respectively.
Smanjenje apetita ili anoreksija sa prosječnim trajanjem od oko 45, odnosno 18 dana.
Decrease in bile flow from the liver
Smanjeno istjecanje žuči iz jetre
decrease in blood calcium and sodium level; increase in blood uric acid level
nižena razina kalcija i natrija u krvi; porast razine mokraćne kiseline u krvi
decrease in blood clotting cells called platelets (that may result in easy bruising and spontaneous bleeding),
manjenje broja krvnih pločica (trombocita) koje sudjeluju u zgrušavanju krvi (što može imati za posljedicu lako nastajanje modrica i spontano krvarenje),
decrease in blood clotting cells called platelets (that may result in easy bruising and spontaneous bleeding),
manjenje broja krvnih pločica (trombocita) koje sudjeluju u zgrušavanju krvi (što može imati za posljedicu lako stvaranje modrica i spontano krvarenje),
decrease in blood clotting cells called platelets that may result in easy bruising and spontaneous bleeding, decrease in certain white blood cells called lymphocytes that help fight infection, decrease in thyroid gland activity (which may make you feel tired, depressed, increase your sensitivity to cold and other symptoms), excess of sugar or uric acid (as in gout) in the blood, low calcium level in the blood, severe anaemia,
manjenje broja krvnih pločica (trombocita) koje sudjeluju u zgrušavanju krvi što može imati za posljedicu lako nastajanje modrica i spontano krvarenje, smanjenje broja određenih bijelih krvnih stanica koje se zovu limfociti, koje pomažu u borbi protiv infekcije, smanjenje aktivnosti štitnjače (zbog čega se možete osjećati umorno, depresivno te biti osjetljiviji na hladnoću ili imati druge simptome), povišena razina šećera ili mokraćne kiseline u krvi (kao kod gihta), niska razina kalcija u krvi, teška anemija,
decrease in blood clotting cells called platelets, that may result in easy bruising and spontaneous bleeding, excess of uric acid (as in gout) in the blood, low calcium level in the blood,
manjenje broja stanica koje zgrušavaju krv, koje se zovu trombociti, što može imati za posljedicu lako nastajanje modrica i spontano krvarenje, povišena razina mokraćne kiseline u krvi (kao kod gihta), niska razina kalcija u krvi,